A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
Scott Gettinger(Yale Cancer Center), Kurt A. Schalper(Yale University)
Cited by 189
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2019|1k